Statins and Cognition in Parkinson’s Disease

Article type: Short Communication

Authors: Deck, Benjamin L.^{a; *} | Rick, Jacqueline^a | Xie, Sharon X.^b | Chen-Plotkin, Alice^a | Duda, John E.^{a; e} | Morley, James F.^{a; e} | Chahine, Lana M.^a | Dahodwala, Nabila^a | Trojanowski, John Q.^c | Weintraub, Daniel^{a; d; e}

Affiliations: [a] Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA | [b] Department of Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA | [c] Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA | [d] Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA | [e] Parkinson’s Disease Research, Education and Clinical Center (PADRECC), Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA

Correspondence: [*] Correspondence to: Benjamin L. Deck, BS, 330 South 9th Street, Philadelphia, PA 19107, USA. Tel.: +1 215 829 7104; Fax: +1 215 829 6606; E-mail: [email protected].

Abstract: Background:The relationship between statins and cognition in Parkinson’s disease (PD) is poorly understood. Objectives:Analyses were performed to determine associations between statin use and cross-sectional and longitudinal cognitive performance in PD. Methods:Neuropsychological tests, medication logs, and ratings of functional abilities were collected from 313 PD participants longitudinally. Results:At baseline, statin users (SU; N = 129) were older, more likely male, and had shorter PD duration than non-statin users (NSU; N = 184). In Cross-sectional analysis, SU performed better on global cognition, Trails B, semantic fluency, and phonemic fluency tasks. Rate of long-term global cognitive (Dementia Rating Scale-2 and MoCA) decline was significantly less in SU.

Keywords: Apolipoprotein A-I, cognition, hydroxymethylglutaryl-CoA reductase inhibitors, longitudinal studies, Parkinson’s disease, reactive oxygen species

DOI: 10.3233/JPD-171113

Journal: Journal of Parkinson's Disease, vol. 7, no. 4, pp. 661-667, 2017